Prothena (PRTA) Expected to Announce Quarterly Earnings on Thursday

Prothena (NASDAQ:PRTA) is projected to post its quarterly earnings results after the market closes on Thursday, February 20th. Analysts expect Prothena to post earnings of ($1.02) per share and revenue of $7.53 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Prothena Trading Down 1.8 %

Shares of PRTA opened at $13.91 on Wednesday. The firm has a market cap of $748.48 million, a P/E ratio of -5.61 and a beta of 0.08. The stock’s 50 day moving average is $14.23 and its two-hundred day moving average is $16.85. Prothena has a 12 month low of $11.70 and a 12 month high of $31.03.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Bank of America decreased their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and set a $48.00 price objective (down previously from $84.00) on shares of Prothena in a research report on Friday, December 20th. Oppenheimer lifted their price objective on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, February 7th. StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. Finally, Chardan Capital initiated coverage on Prothena in a research report on Friday, December 20th. They set a “buy” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.50.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.